Craig M. Brackett, Ph.D.
Affiliations: | 2012 | Biological Sciences | State University of New York, Buffalo, Buffalo, NY, United States |
Area:
ImmunologyGoogle:
"Craig Brackett"Parents
Sign in to add mentorSandra O. Gollnick | grad student | 2012 | SUNY Buffalo | |
(Modulation of the Immune Response by IL-17 Following Photodynamic Therapy.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Shah SD, Gillard BM, Wrobel MM, et al. (2023) Syngeneic model of carcinogen-induced tumor mimics basal/squamous, stromal-rich, and neuroendocrine molecular and immunological features of muscle-invasive bladder cancer. Frontiers in Oncology. 13: 1120329 |
Ivanick NM, Oakley ER, Kunadharaju R, et al. (2022) First-In-Human Computer-Optimized Endobronchial Ultrasound-Guided Interstitial Photodynamic Therapy for Patients With Extrabronchial or Endobronchial Obstructing Malignancies. Jto Clinical and Research Reports. 3: 100372 |
Chen M, Brackett CM, Burdelya LG, et al. (2021) Stimulation of an anti-tumor immune response with "chromatin-damaging" therapy. Cancer Immunology, Immunotherapy : Cii |
Haderski GJ, Kandar BM, Brackett CM, et al. (2020) TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects. Plos One. 15: e0227940 |
Mett V, Komarova EA, Greene K, et al. (2017) Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy. Oncogene |
Brackett CM, Kojouharov B, Veith J, et al. (2016) Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis. Proceedings of the National Academy of Sciences of the United States of America |
Brackett C, Kojouharov B, Gollnick S, et al. (2016) Abstract B090: A Toll-like receptor 5 agonist entolimod as a potential anticancer immunotherapeutic agent Cancer Immunology Research. 4 |
Yang H, Brackett CM, Morales-Tirado VM, et al. (2015) The toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism. Oncotarget |
Kojouharov BM, Brackett CM, Veith JM, et al. (2014) Toll-like receptor-5 agonist Entolimod broadens the therapeutic window of 5-fluorouracil by reducing its toxicity to normal tissues in mice. Oncotarget. 5: 802-14 |
Brackett CM, Muhitch JB, Evans SS, et al. (2013) IL-17 promotes neutrophil entry into tumor-draining lymph nodes following induction of sterile inflammation. Journal of Immunology (Baltimore, Md. : 1950). 191: 4348-57 |